Streetbeat News

Price Targets

GMDA

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Gamida Cell (NASDAQ:GMDA) but reduced the price target from $5 to $2 as reported on November 14, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:34 pm

RMTI

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Rockwell Medical (NASDAQ:RMTI) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:34 pm

GMDA

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Gamida Cell (NASDAQ:GMDA) but reduced the price target from $5 to $2.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:33 pm

YPF

Goldman Sachs analyst Bruno Amorim has reiterated a Sell rating on YPF (NYSE:YPF) and reduced the price target from $9.5 to $8.5.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:30 pm

IHRT

Goldman Sachs analyst Stephen Laws has maintained a Neutral rating on iHeartMedia (NASDAQ:IHRT) but has reduced the price target from $3 to $2.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:28 pm

ALNY

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $395.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:28 pm

GWRE

Goldman Sachs analyst Kevin Kumar has reaffirmed a Buy rating on Guidewire Software (NYSE:GWRE) and increased the price target from $103 to $115.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:27 pm

ACXP

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Acurx Pharmaceuticals (NASDAQ:ACXP) and maintained a $13 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:24 pm

AMAM

Goldman Sachs analyst Corinne Jenkins has maintained a Neutral rating on Ambrx Biopharma (NASDAQ:AMAM) and reduced the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:24 pm

SHPW

Needham analyst James Ricchiuti has reiterated a Buy rating on Shapeways Holdings (NASDAQ:SHPW) and maintained a $4 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 3:20 pm